Tuesday, April 19, 2022
3:00 PM – 4:00 PM (EST)
No registration is required to participate - the Series is free and open to anyone. To participate, login with your ASCO.org username and password. Create a new, free account or for assistance with your existing login.
Kimmie Ng, MD, MPH
Dana-Farber Cancer Institute
Welcome and Introduction
Sharon Spencer, MD– Panel Moderator
University of Alabama at Birmingham
Li Zhang, MD
Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China and Sun Yat-sen University Cancer Center
Abstract 384950: RATIONALE-309: Updated progression-free survival (PFS), PFS after next line of treatment, and overall survival from a phase 3 double-blind trial of tislelizumab versus placebo, plus chemotherapy, as first-line treatment for recurrent/metastatic nasopharyngeal cancer.
Robert I. Haddad, MD
Dana-Farber Cancer Institute, Harvard Medical School
Discussion of Abstract 384950
Panel Question and Answer with Drs. Zhang and Haddad, Moderated by Dr. Sharon Spencer